Department of Orthopedics, Fuzhou General Hospital of Nanjing Command, PLA, FuZhou 350025, China.
Department of Endocrinology, Fuzhou General Hospital of Nanjing Command, PLA, FuZhou 350025, China.
Complement Ther Clin Pract. 2017 Aug;28:152-160. doi: 10.1016/j.ctcp.2017.06.003. Epub 2017 Jun 8.
OBJECTIVE: Cupping therapy is widely used in East Asia, the Middle East, or Central and North Europe to manage the symptom of knee osteoarthritis (KOA). The purpose of this systematic review was to evaluate the available evidence from randomized controlled trials (RCTs) of cupping therapy for treating patients with KOA. METHODS: The following databases were searched from their inception until January 2017: PubMed, Embase, the Cochrane Central Register of Controlled Trials and four Chinese databases [WanFang Med Database, Chinese BioMedical Database, Chinese WeiPu Database, and China National Knowledge Infrastructure (CNKI)]. Only the RCTs related to the effects of cupping therapy on KOA were included in this systematic review. A quantitative synthesis of RCTs will be conducted using RevMan 5.3 software. Study selection, data extraction, and validation was performed independently by two reviewers. Cochrane criteria for risk-of-bias were used to assess the methodological quality of the trials. RESULTS: Seven RCTs met the inclusion criteria, and most were of low methodological quality. Study participants in the dry cupping therapy plus the Western medicine therapy group showed significantly greater improvements in the pain [MD = -1.01, 95%CI (-1.61, -0.41), p < 0.01], stiffness [MD = -0.81, 95%CI (-1.14, -0.48), p < 0.01] and physical function [MD = -5.53, 95%CI (-8.58, -2.47), p < 0.01] domains of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) compared to participants in the Western medicine therapy group, with low heterogeneity (Chi = 0.00 p = 1.00, I = 0% in pain; Chi = 0.45 p = 0.50, I = 0% in stiffness; Chi = 1.09 p = 0.30, I = 9% in physical function). However, it failed to do so on a Visual Analog Scale (VAS) [MD = -0.32, 95%CI (-0.70, 0.05), p = 0.09]. In addition, when compared with Western medicine therapy alone, meta-analysis of four RCTs suggested favorable statistically significant effects of wet cupping therapy plus western medicine on response rate [MD = 1.06, 95%CI (1.01, 1.12), p = 0.03; heterogeneity: Chi = 1.13, p = 0.77, I = 0%] and Lequesne Algofunctional Index (LAI) [MD = -2.74, 95%CI (-3.41, -2.07), p < 0.01; heterogeneity: Chi = 2.03, p = 0.57, I = 0% ]. CONCLUSION: Only weak evidence can support the hypothesis that cupping therapy can effectively improve the treatment efficacy and physical function in patients with KOA.
目的:拔罐疗法在东亚、中东或中欧被广泛用于治疗膝骨关节炎(KOA)的症状。本系统评价的目的是评估来自随机对照试验(RCT)的关于拔罐疗法治疗 KOA 患者的可用证据。
方法:从数据库成立开始到 2017 年 1 月,我们检索了以下数据库:PubMed、Embase、Cochrane 对照试验中心注册库和四个中文数据库[万方医学数据库、中国生物医学数据库、中国维普数据库和中国国家知识基础设施(CNKI)]。本系统评价仅纳入与拔罐疗法对 KOA 影响相关的 RCT。使用 RevMan 5.3 软件对 RCT 进行定量综合。两位评审员独立进行研究选择、数据提取和验证。采用 Cochrane 偏倚风险标准评估试验的方法学质量。
结果:有 7 项 RCT 符合纳入标准,其中大多数为低质量研究。与西药治疗组相比,干拔罐治疗联合西药治疗组的患者在 Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)疼痛[MD=-1.01,95%CI(-1.61,-0.41),p<0.01]、僵硬[MD=-0.81,95%CI(-1.14,-0.48),p<0.01]和身体功能[MD=-5.53,95%CI(-8.58,-2.47),p<0.01]方面的改善明显更大,且差异具有统计学意义(疼痛领域的 Chi²=0.00,p=1.00,I²=0%;僵硬领域的 Chi²=0.45,p=0.50,I²=0%;身体功能领域的 Chi²=1.09,p=0.30,I²=9%)。然而,在视觉模拟量表(VAS)上,差异无统计学意义[MD=-0.32,95%CI(-0.70,0.05),p=0.09]。此外,四项 RCT 的荟萃分析表明,与单独西药治疗相比,湿拔罐联合西药治疗对反应率具有统计学意义上的显著有利影响[MD=1.06,95%CI(1.01,1.12),p=0.03;异质性:Chi²=1.13,p=0.77,I²=0%]和 Lequesne Algofunctional Index(LAI)[MD=-2.74,95%CI(-3.41,-2.07),p<0.01;异质性:Chi²=2.03,p=0.57,I²=0%]。
结论:仅有弱证据支持拔罐疗法可有效提高 KOA 患者治疗效果和身体功能的假设。
Complement Ther Clin Pract. 2017-6-8
Complement Ther Clin Pract. 2018-7-6
Complement Ther Clin Pract. 2018-3-15
Cochrane Database Syst Rev. 2018-4-17
Cochrane Database Syst Rev. 2022-10-21
Complement Med Res. 2018
Cochrane Database Syst Rev. 2022-9-23
Cochrane Database Syst Rev. 2017-5-22
Front Neurol. 2023-10-26
Arthroplast Today. 2022-3-18
Mediterr J Rheumatol. 2021-12-27
J Healthc Eng. 2022
J Clin Med. 2021-4-17
Front Bioeng Biotechnol. 2020-12-8